Register Here

2020 Agenda

  • 7:30 am

  • Registration

  • 8:15 am

  • Co-Chair's Opening Remarks


    Axel Hoos, MD, PhD

    SVP, Oncology R&D, GSK


    James Gulley, MD, PhD

    Chief, Genitourinary Malignancies Branch, Director, Medical Oncology Service, Center for Cancer Research, National Cancer Institute, NIH

  • 8:25 am

  • Opening Keynote: T Cell Therapy for Cancer


    Carl June, MD

    Richard W. Vague Professor in Immunotherapy at the Department of Pathology and Laboratory Medicine; Director, Center for Cellular Immunotherapies at the Perelman School of Medicine; Director, Parker Institute for Cancer Immunotherapy, University of Pennsylvania


  • Discovery/Preclinical Science Plenary Session

  • 8:55 am

  • Overview Talk on the Biology of Targeted Cytokine Delivery

    Pablo Umaña
    Pablo Umaña, PhD

    Head, Cancer Immunotherapy Discovery, Pharma Research and Early Development, Roche

  • 9:15 am

  • Safely Targeting TGF Beta, Challenges and Opportunities


    Rik Derynck, PhD

    Professor, Departments of Cell/Tissue Biology and Anatomy, University of California San Francisco

  • 9:35 am

  • Grand Opening of the Exhibit & Networking Café and Breakfast

  • 10:20 am

  • Updates on IL-15

    John Desjarlais
    John Desjarlais, PhD
    SVP, Research & CSO, Xencor

  • 10:40 am

  • Off-the-Shelf Cell-based Cancer Immunotherapy for Mass Production of Precisely Engineered Allogeneic T Cell and NK Cell Products Derived from (iPSC) Master Cell Lines

    This talk will discuss and outline the roadmap for development of off-the-shelf cell therapies based on engineered T cells and natural killer (NK) cells derived from induced pluripotent stem cell (iPSC) master cell lines. The presentation will highlight single cell engineering for precise editing of unique genetic input, creation of clonal master cell banks for the renewable source of consistent and low-cost large scale manufacturing, and the anti-tumor efficacy of engineered T and NK cells designed with unique attributes to improve safety and potency.

    Valamehr
    Bahram (Bob) Valamehr, PhD

    Chief Development Officer, Fate Therapeutics

  • 10:55 am

  • Epigenetic Priming of the Tumor Microenvironment Synergizes with NHS-IL12 to Promote Effective Tumor Control

    Sofia Gameiro
    Sofia Gameiro, PhD

    Staff Scientist & Head, Immunomodulation Group,  Laboratory of Tumor Immunology and Biology, National Cancer Institute

  • 11:15 am

  • Immune Landscape Signatures for Tumor Microenvironment Characterization and Therapy Response

    Patrice Hugo
    Patrice Hugo, PhD

    CSO, Q² Solutions

  • 11:30 am

  • Neoantigen Vaccine Processing and Algorithms for Predicting Peptide Structure


    Roman Yelensky, PhD

    EVP & Chief Technology Officer, Gritstone Oncology

  • 11:50 am

  • Payload Oncolytic Virus’: Viral Delivery of Genes that Allow for Local Production of Immune Modulators

  • 12:10 pm

  • Lunch & Partnering Meetings

  • 1:10 pm
    - 3:40 pm

  • Track Choices

    • TRACK A

      Imaging Aspects

      1:10 pm

      Updates on Avelumab Study Comparing Investigator Assessments Using RECIST 1.1 and Immune RECIST


      S. Peter Eggleton, MD, FFPM

      Medical Director, GCDC Oncology, Merck KGaA


      1:30 pm

      IO Criteria in the Brain

      This talk will discuss the immunotherapy response assessment for neuro-oncology (iRANO) criteria, pros and cons along with case studies and examples.

      Bohnsack_Oliver
      Oliver Bohnsack, MD, PhD

      VP, Scientific and Medical Services, Medical Imaging, Head of Oncology, Parexel


      Manuela Lesch

      Director, Scientific and Medical Services, Parexel Informatics


      1:50 pm

      Inter-tumor Growth Dynamics Signature Differences in IO

      Dean Bottino
      Dean Bottino, PhD

      Senior Scientific Director, Clinical Translational Modeling & Simulation Leader, Takeda


      2:10 pm

      New Imaging Technologies for Evaluation of Immune Response 

      Ron Korn
      Ron Korn, MD, PhD

      Founder, Chairman and CMO, Imaging Endpoints


      2:30 pm

      LN Enlargement as a Predictor of Immune Response


      Laurent Dercle, MD

      Associate Research Scientist, Columbia University Medical Center


      2:50 pm

      Using Technology to Address Challenges in Implementation & Monitoring of IO Criteria

      Amit Vasanji
      Amit Vasanji, PhD

      Chief Technology Officer, Oncology, ERT


      3:05 pm

      Panel: Innovations & Novel Approaches in IO Imaging & Assessing Responses 

      Moderated by:

      Annette Schmidt
      Annette Schmid, PhD

      Senior Scientific Director, Clinical Imaging Scientist, Takeda Pharmaceuticals

      Panelists:

      Gregory Goldmacher
      Gregory Goldmacher, MD, PhD

      Executive Director, Translational Biomarkers, Head of Clinical Imaging, Merck


      S. Peter Eggleton, MD, FFPM

      Medical Director, GCDC Oncology, Merck KGaA

      Ron Korn
      Ron Korn, MD, PhD

      Founder, Chairman and CMO, Imaging Endpoints


      Matthew Silva, PhD

      EVP, Scientific Applications, Invicro

    • TRACK B

      Clinical Operations

      1:10 pm

      Operational Strategy in T cell Engagers / Bispecific Studies 

      • Clinical Trial Design 
      • Landscape, Feasibility & Recruitment 
      • Managing toxicities in Bispecifics
      • Challenges & Opportunities

      Iris Sisson
      Iris Sisson

      Head of Clinical Operations, IGM Biosciences


      1:30 pm

      CRO Case Study

       

       


      1:50 pm

      Operational Dynamics of Implementing & Managing Basket Trials

      • What are the operational complexities of basket trials? How do they differ from standard IO trials?
      • How do you identify the right institutions who can handle basket trials? What goes into that decision making?
      • How do you set up your protocol in an open ended way so that you can add a cohort or make adjustments based on signals you received?
      • How do you set up your database to be able to manage all the different tumor types and different types of case port forms.

      Millie Shultz
      Millie Shultz

      Senior Director, Regional Clinical Trial Operations, Seattle Genetics


      2:10 pm

      CRO Case Study

       

       


      2:30 pm

      Panel: How Can Sites, Sponsors and Patients Work Together to Enable Optimal Oncology Drug Development?

      Panelists: 

      Andy Lee
      Andy Lee

      SVP, Head of Global Clinical Trial Operations, Merck


      Archana Sah

      Chair, Oncology Board, Society for Clinical Research Sites

      Beth Metzheiser
      Beth Metzheiser

      Head of Clinical Operations, Hematology and CRO Collaborations, BMS

      Speaker TBD, Covance 

      Speaker TBD, Medidata

  • 3:40 pm

  • Afternoon Networking Break and Partnering Meetings


  • Next Generation Bispecifics Plenary Session

  • 4:25 pm

  • Bispecific Antibodies in Cancer Immunotherapy

    • Bispecific Antibodies overview (history, latest developments in Ab engineering, bispecific vs CAR-Ts)
    • An emerging class of immunotherapeutics: CD3x bispecifics in hematologic malignancies
    • A novel platform of costimulatory bispecifics antibodies to enhance the anti-tumor efficacy of existing therapies

    Dimitris Skokos
    Dimitris Skokos, PhD

    Director, Immunology & Inflammation, Regeneron Pharmaceuticals

  • 4:45 pm

  • Cytokine Release Syndrome with Bispecifics and CART

    This talk will also cover the efficacy, toxicity and ways to tackle toxicity.

    Grupp_Stephan
    Stephan Grupp, MD, PhD

    Chief, Cellular Therapy and Transplant Section, Children’s Hospital Of Pennsylvania (CHOP) 

  • 5:05 pm

  • T cell Therapeutics to Treat Hematological Malignancies and Solid Tumors

    T cell therapeutics have demonstrated clinical benefit in hematological malignancies and there is growing evidence of activity in solid tumors.  This presentation will describe key findings from recent trials along with observations from nonclinical studies that inform on mechanism of action and approaches to address clinically-observed challenges.

    Tara Arvedson
    Tara Arvedson, PhD

    Executive Director, Oncology Research, Amgen

  • 5:25 pm

  • Cancer Immunotherapy Debate: Bispecifics vs Cell Therapies


    Carl June, MD

    Richard W. Vague Professor in Immunotherapy at the Department of Pathology and Laboratory Medicine; Director, Center for Cellular Immunotherapies at the Perelman School of Medicine; Director, Parker Institute for Cancer Immunotherapy, University of Pennsylvania

    vs

    Daniel Dan Chen
    Daniel Chen, MD, PhD

    Chief Medical Officer, IGM Biosciences

  • 5:45 pm

  • Next Generation Bispecifics in Solid Tumors

    • What is happening in hematology bispecific programs compared to solid tumor bispecific programs?
    • What do bispecifics look like in solid tumors and what is driving efficacy?
    • Whats hindering efficacy in solid tumors compared to hematology?
    • How can we improve on it?
    • What should we be doing on the next generation bispecifics?

    Moderated by:


    Priti Hedge, PhD

    Chief Scientific Officer, Foundation Medicine

    Panelists:

    Dimitris Skokos
    Dimitris Skokos, PhD

    Director, Immunology & Inflammation, Regeneron Pharmaceuticals

    Tara Arvedson
    Tara Arvedson, PhD

    Executive Director, Oncology Research, Amgen

    David Schaer
    David Schaer, PhD

    Director, Translational Oncology Lead, Pfizer

    Pablo Umaña
    Pablo Umaña, PhD

    Head, Cancer Immunotherapy Discovery, Pharma Research and Early Development, Roche

  • 6:30 pm

  • End of Day One

2020 Agenda

  • 7:45 am

  • Registration

  • 8:15 am

  • Co-Chair's Opening Remarks


    Ian McCaffery, PhD

    VP, Oncology Translational Science, Janssen R&D


    Andrew Baum, MD

    Head of Global Healthcare; Managing Director, Equity Research, Citi

  • 8:25 am

  • Opening Keynote


    Arie Belldegrun, MD, FACS

    Executive Chairman & Co-founder, Allogene

  • 8:50 am

  • Financial Keynote: Evaluation and Forecast of the IO Space


    Andrew Baum, MD

    Head of Global Healthcare; Managing Director, Equity Research, Citi

  • 9:15 am

  • Opening of the Exhibit & Networking Café, Breakfast & Partnering Meetings

  • 9:55 am
    - 6:15 pm

  • Choice between Business Developments, Translational Science & Emerging Biomarkers and Cell & Gene Therapy Day

    One day rates are available for Cell & Gene Therapy Day. Please click here for more information.

    • TRACK A

      Business Developments Plenary Session

      Chaired by:


      Andrew Baum, MD

      Head of Global Healthcare; Managing Director, Equity Research, Citi


      9:55 – 10:15 am

      The Endpoints News Report

      Carroll_John
      John Carroll

      Editor-in-Chief, Endpoints News


      10:15 – 11:00 am

      What Do Next Generation of Immunotherapies Need to Look Like to Move the Needle?

      The frenzy of deals around IO programs and companies has led to what could be referred to as “BD outpacing science.” That might be said too of the combination trials that have displayed varied results, with a few showing clear benefit, some being outright failures and some promising but not definitive signs of efficacy. These results, while not exactly slowing the IO gold rush, have somewhat tempered enthusiasm and perhaps led to a certain maturing in dealmaking, as seen by the shifting to more back-loaded terms. Which is all by way of framing the context of the macroenvironment, which now begs the question of where will the next big shift come from in immunotherapy.

      • Will it be innovative cell therapies, vaccines against neoantigens, or the next wave of oncolytic viruses? 
      • Will it be known targets with better approaches to modulating them like TGF-beta, A2AR/CD73, even CTLA-4? 
      • Will it be novel targets and pathways targeting transcription or hitting new TNF superfamily members, or new approaches to modulate the TME “bad actors” like MDSCs, CAFs, TAMs, TANs and Tregs?

      This panel will tie together discussion on scientific, translational and business development considerations into the latest thinking on strategizing development in IO that will impact collaborations and investment decision making.

      Led by:

      Jeffrey Bockman
      Jeffrey Bockman, PhD

      EVP & Head, Oncology Practice, Cello Health BioConsulting

      Panelists:

      Charles Drake
      Charles Drake, MD, PhD

      Director Genitourinary Oncology Co-Director Immunotherapy Associate Director, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center

      Asthika Goonewardene
      Asthika Goonewardene, MBA

      Managing Director, Senior Biotech Analyst, SunTrust Robinson Humphrey

      Bibash
      Bibhash Mukhopadhyay, PhD

      Principal, New Enterprise Associates


       

      IO Novel Technologies

      11:00 – 11:50 am

      This session showcases companies that have technologies and solutions that will help stakeholders in the IO field advance developments that provide treatment for cancer patients.

      Participating Companies:

       
       
       
       

       


       

      Translational Science & Biomarkers

      11:50 am – 12:10 pm

      Suppressive Cells in the Tumor Microenvironment 

      Charles Drake
      Charles Drake, MD, PhD

      Director Genitourinary Oncology Co-Director Immunotherapy Associate Director, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center


      12:10 – 12:30 pm

      Mitra Biotech Case Study


      12:30 – 1:30 pm

      Lunch & Partnering Meetings


      1:30 – 1:50 pm

      Cancer Immunotherapy Debate: Insitu Vaccinations vs Systemic Neo-Epitope Vaccinations

      Charles Drake
      Charles Drake, MD, PhD

      Director Genitourinary Oncology Co-Director Immunotherapy Associate Director, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center


      1:50 – 2:10 pm

      New Biomarkers for I-O Efficacy

      Weber_Jeffrey
      Jeff Weber, MD, PhD

      Deputy Director, Perlmutter Cancer Center; Co-Director, Melanoma Program & Head of Experimental Therapeutics, NYU Langone Medical Center


      2:10 – 2:30 pm

      A New Generation of Multidimensional Biomarkers for Immune Composition and Cell State Fueled by RNA Models 

      • Why legacy single-analyte tools have hindered precision medicine
      • How multidimensional models can be built and leveraged for immune profiling; including cell composition, state (e.g. exhaustion), and biomarker discovery
      • Translating tools from the single-laboratory setting to a decentralized model


      Jarret Glasscock, PhD

      CEO, Cofactor Genomics


      2:30 – 2:50 pm

      Reserved Talk


      2:50 – 3:05 pm

      Translational Science Driving Combinatorial Strategies

      Chris Boshoff
      Chris Boshoff, FRCP, FMedSci, PhD

      Chief Development Officer, Pfizer Oncology


      3:05 – 3:25 pm

      Reserved Talk


      3:25 – 4:05 pm

      Afternoon Networking Break & Partnering Meetings


      4:05 – 4:25 pm

      TMB and PDL1: The Next Chapter

      This talk will briefly review how TMB entered the conversation in IO, followed by a review of recent data on TMB and PD-L1 and their potential implications for next steps in patient treatment and study designs.

      Alexandra Snyder
      Alexandra Snyder, MD

      Head, Translational Oncology / Executive Director, Oncology Early Development, Merck Research Labs


      4:25 – 4:40 pm

      Reserved Talk


      4:40 – 4:55 pm

      Reserved Talk


      4:55 – 5:45 pm

      Panel: Mechanisms and Biomarkers of Resistance in the Era of IO Combination Therapy

      Given the number of combination therapies that are ongoing, one of the ways in which one can prioritize combinations is by assessing the translatability of the preclinical biology into the clinic. We do realize there are challenges associated with this including biological translation and challenges with the tools and technologies available for us to assess biology robustly in patients. This panel will discuss where we stand today, identify the key challenges we are facing and explore the opportunities we have to address those gaps.

      Moderated by: 


      Priti Hedge, PhD

      Chief Scientific Officer, Foundation Medicine

      Panelist:

      Alexandra Snyder
      Alexandra Snyder, MD

      Head, Translational Oncology / Executive Director, Oncology Early Development, Merck Research Labs


      5:45 pm

      End of Day Two

    • TRACK B

      Cell & Gene Therapy Day

      Chaired by:


      Aiman Shalabi, PharmD

      VP R&D, Cell and Gene Therapies, GSK


      9:55 – 10:40 am

      Landscape and Evolution of the Marketplace

      Led by:

      Brad Loncor
      Brad Loncor

      CEO, Loncor Investments

      Panelists:

      Vanessa Lucey
      Vanessa Lucey, PhD

      Director, CRI Venture Fund and Clinical Accelerator, Cancer Research Institute

      Janet Lambert
      Janet Lynch Lambert

      CEO, Alliance for Regenerative Medicine


      Adrian McKemey, PhD

      Managing Director and Head of R&D Strategy Solutions, IQVIA


      10:40 – 11:40 am

      Innovation Hour: New Scientific Frontiers in Cell Therapies for Solid Tumors

      Led by:

      Crystal Mackall
      Crystal Mackall, MD

      Professor of Pediatrics and Medicine; Director, Stanford Center for Cancer Cell Therapy; Director, Parker Institute for Cancer Immunotherapy at Stanford; Associate Director, Stanford Cancer Institute, Stanford University School of Medicine


       

      Cell Therapy Pivotal Pharma Developments for Solid Tumors

      11:40 am – 12:00 pm

      TILS Targeting Individual Tumor Mutations

      Stephanie Goff
      Stephanie Goff, MD

      Associate Research Physician, Surgery Branch, National Cancer Institute, NIH


      12:00 – 12:15 pm

      Investigating the Power of Tumor Infiltrating Lymphocytes for Treatment of Cancer


      Maria Fardis, PhD

      President and CEO, IOVANCE Biotherapeutics


      12:15 – 12:35 pm

      Update on NY-ESO


      Aiman Shalabi, PharmD

      VP R&D, Cell and Gene Therapies, GSK


      12:35 – 1:30 pm

      Lunch & Partnering Meetings


      1:30 – 1:50 pm

      Virus Specific T Cells as Platform for Solid Tumor Immunotherapy

      The ability to simultaneously monitor changes in multiple immune parameters holds great discriminatory and instructive power for the purpose of biomarker validation and mechanistic target discovery. In the case of Virus Specific T cell therapy for solid tumors, an examination of the systemic, cellular and local immune environment during the course of treatment has yielded a series of predictive biomarkers correlating with immunogenicity, response to therapy and overall survival on trial.  An analysis of antigen specific T-cells have identified anti-viral responses with positive prognostic value. Differences in the immunosuppressive state of the patient’s activated regulatory T-cells (Tregs) and the expansion or contraction of the myeloid-derived suppressor cell (MDSC) compartment, point to a mechanism of action for the therapy.


      John Connolly, PhD

      Chief Scientific Officer, Tessa Therapeutics Ltd


      1:50 – 2:05 pm

      Evidence-based Accelerators for Early Phase IO Clinical Development  

      How can you use innovation and calculated risk to accelerate development of cell therapies?  In this talk, IQVIA discusses modeling of IO data to develop new types of strategies vs. modeling strategies to develop new types of evidence.  Lessons learned from early cell therapy entrants on finding, recruiting and following the ‘right’ patients will also be presented.


      Chris Learn, PhD

      Senior Therapeutics Strategy Director, Cell and Gene Therapy, IQVIA


      2:05 – 2:25pm

      Current and Future Innovations Toward GMP Manufacturing of CAR and TCR Engineered T cells

      Paglia_Michael
      Michael Paglia

      VP, CMC Operations, ElevateBio


      2:25 – 2:40 pm

      Reserved Talk


      2:40 – 3:25 pm

      Panel: Evolution of Regulatory Policy For Cell/Gene Therapy

      Moderator:

      Peter Marks
      Peter Marks, MD, PhD

      Director, Center for Biologics Evaluation and Research (CBER), FDA

      Panelists:


      Jeff Allen, PhD

      President & CEO, Friends of Cancer Research

      Anne Chew
      Anne Chew, PhD

      Executive Deputy Director, Center for Cellular Immunotherapies, University of Pennsylvania

      Additional Panelists TBD


      3:25 – 4:05 pm

      Afternoon Networking Break & Partnering Meetings


       

      Moving Beyond Pharma: New Collaborative Development Paradigms for Cell Therapies

      4:05 – 4:15 pm

      Master Protocol for Cell/ Gene Therapies and Parker Institutes Efforts/Innovations in Cell Therapy


      Ramy Ibrahim, MD

      Chief Medical Officer and VP, Clinical Development, Parker Institute for Cancer Immunotherapy


      4:15 – 4:25 pm

      Unlocking Trapped Innovation in Cell, Gene Therapy & Regenerative Medicine

      Finer_Mitch
      Mitch Finer, PhD

      CSO, President and Executive Partner, ElevateBio


      4:25 – 4:35 pm

      Cancer Therapy Evaluation Program Innovations in Cell Therapy (CTEP)

      Sharon_Elad
      Elad Sharon, MD

      Senior Investigator, Cancer Therapy Evaluation Program (CTEP), National Cancer Institute


      4:35 – 4:45 pm

      Canadian Cancer Trials Group (CCTG)

      Speaker TBD


      4:45 – 5:15 pm

      Panel: New Collaborative Development Paradigms for Cell Therapies

      Led by:


      Ramy Ibrahim, MD

      Chief Medical Officer and VP, Clinical Development, Parker Institute for Cancer Immunotherapy

      Panelists:

      Finer_Mitch
      Mitch Finer, PhD

      CSO, President and Executive Partner, ElevateBio

      Sharon_Elad
      Elad Sharon, MD

      Senior Investigator, Cancer Therapy Evaluation Program (CTEP), National Cancer Institute


       

      Cell & Gene Therapy Debates

      5:15 – 5:35 pm

      Combinations with Checkpoints

      Christina Coughlin
      Christina Coughlin, MD, PhD

      EVP & CMO, Tmunity

      vs

      Priceman
      Saul Priceman, PhD

      Assistant Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope


      5:35 – 5:55 pm

      Bedside Manufacturing vs Centralized Manufacturing


      Boro Dropulić, PhD

      Chief Science Officer & General Manager, Lentigen

  • 6:00 pm

  • Annual Networking Reception

2020 Agenda

  • 7:45 am

  • Registration

  • 8:15 am

  • Co-Chair's Opening Remarks

    Daniel Dan Chen
    Daniel Chen, MD, PhD

    Chief Medical Officer, IGM Biosciences


    Jacqueline Karmel

    Group Global Scientific Director / Chair, imCORE Executive Committee, Roche

  • 8:25 am

  • Patient Keynote Fireside Chat

    Moderator:


    Cindy Geoghegan

    Patient Advocate

    VIP Patient Guest:

    Perlmutter_Jane
    Jane Perlmutter, PhD

    Cancer Survivor and Advocate


  • AI & Machine Learning Plenary Session 

  • 8:55 am

  • AI & Machine Learning in R&D

    This talk will provide an overview of how AI & Machine Learning is being used in drug discovery and development and how it is applicable to the cancer immunotherapy field. 


    Kim Branson, PhD

    SVP, Global Head, Artificial Intelligence and Machine Learning, GSK

  • 9:15 am

  • Machine Learning for Tumor and Cell Segmentation and Cell Classification within the Tumor Microenvironment

    Machine/Deep learning methods for the analysis of the tumor microenvironment can greatly aid oncological research through the automation of largely manual tasks. Using their proprietary analytics workflow, NeoGenomics presents results for tumor segmentation, cell segmentation and classification for CD8 and PD-L1, and spatial analytics, which will provide attendees with a deeper understanding of the effect that automation has on analytics precision and time-saving, and how it enables the generation of large volumes of data that were not possible just a couple of years ago.


    Máté Levente Nagy, PhD

    Senior Scientist & Technical Lead, Computational Biology, NeoGenomics Laboratories, Inc

  • 9:35 am

  • Networking Café, Morning Break and Breakfast, Partnering Meetings

  • 10:20 am

  • Using Machine Learning to Extract Meaningful Insights for Cancer Immunotherapy

    Led by:


    Matthew Albert, MD, PhD

    VP, Immunology & Infectious Diseases, Insitro

    Panelists: 


    Kim Branson, PhD

    SVP, Global Head, Artificial Intelligence and Machine Learning, GSK

    Stumpe_Martin
    Martin Stumpe, PhD

    SVP, Data Science, Tempus

    Additional Panelists TBD


  • IO Clinical Developments

  • 11:00 am

  • Next Generation Checkpoints in the Clinic

    This talk gives a comprehensive assessment on IDO, A2A, TGF, LAG3, TIM3 and other antagonist antibodies. Addressing:

    • What are they really delivering?
    • Why aren’t they showing more?
    • Are they likely to be effective therapies in combination with pd1 or are they going to be met?
  • 11:20 am

  • Agonist Abs to TNF Receptor Family Members

    This talk provides a summary of Abs to TNFR family members and their advances to the clinic (OX40, 4-1BB, CD27, GITR and CD40).  In particular, OX40 agonists will be the focus of this talk and their effects on targeting T cells within the tumor microenvironment. Optimal dose and scheduling of OX40 agonists will also be reviewed.


    Andy Weinberg, PhD
    Chief, Laboratory of Basic Immunology at the Robert W. Franz Cancer Research Center, Providence Cancer Center / CSOAgonOx

  • 11:50 am

  • Clinical Development of ICOS Agonist Antibodies


    Axel Hoos, MD, PhD

    SVP, Oncology R&D, GSK

  • 12:10 pm

  • Clinical Review of TGF Beta Trap PDL1 Bispecific Antibody


    Olaf Christensen, MD

    Vice President, Global Development and R&D, Head, TGF-beta TRAP, EMD Serono

  • 12:30 pm

  • Lunch on Own & Partnering Meetings

  • 1:30 pm

  • Update on Merck’s IO Clinical Developments


    Roy Baynes, MD, PhD

    SVP & Head, Global Clinical Development, Chief Medical Officer, Merck Research Laboratories

  • 1:50 pm

  • Novel Approaches to IO-IO Combinations

    Lee_James
    Lee James, MD, PhD

    Clinical Program Lead, Early Clinical Development, Oncology, BMS

  • 2:10 pm

  • HLA Loss and the Impact on Immunotherapy

    Loss of the HLA locus impairs presentation of tumor antigens and is frequently found in advanced cancers. This talk will describe the landscape of HLA loss and other response biomarkers in a dataset of 90,000 solid tumor samples and highlight the effect of HLA loss on checkpoint inhibitor response.


    Lee A Albacker, PhD
    Director, Cancer Genomics Research, Foundation Medicine

  • 2:20 pm

  • Advancements in IO Combination Trial Platforms

    Some of the newer combination platforms are producing data that reflects combinations with PD1/PDL1 inhibitors. We now have a better understanding of actual data and how signals come out of a trial like this. We will feature 10-15 minute talks that include combination platforms such as MORPHEUS, FRACTION, etc.

  • 4:00 pm

  • Conference Concludes